Amid slower-than-anticipated sales of its second-line pancreatic cancer drug Onivyde (irinotecan liposome injection), Merrimack Pharmaceuticals Inc. president and CEO Robert Mulroy resigned and the company moved to cut 22 percent of its work force in a major restructuring it said would prioritize its R&D efforts and eliminate more than $200 million in expected costs over the next two years.